We have brought together a stellar team of leading immunology drug developers, machine learning innovators and company builders who are charting new drug discovery territory to open better and faster ways to make medicines for patients with autoimmune and other immunological diseases. Guided by an experienced board of directors and world renowned scientific founders, Seismic is a product-centric, patient-focused immunology company with a growing biologics pipeline to control dysregulated adaptive immunity, derived from our machine-learning IMPACT platform.
Our combination of exceptional talent, inclusive integration, and strong resolve will enable us to reach untapped biology of the adaptive immune system and make a major impact on treating autoimmune diseases. Jo is a seasoned biotech executive and entrepreneurial scientist who has taken more than a dozen drugs to clinic over her year career. Prior to Pandion, she held research leadership positions at Biogen, Amgen and Immunex.
She is an experienced director on both private and public company boards. Jo is an advocate for workplace inclusiveness and regularly volunteers her time with organizations focused on increasing diversity. She has served on the board of WEST, a non-profit organization supporting early to mid-career women, including as President John is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry.
His research career has focused on developing novel therapies for patients with inflammatory and fibrotic diseases. He is an Independent Director of Sanofi S. While at Duke he was instrumental in the Phase development of Krystexxa which is approved for patients with refractory gout.
An undergraduate from Bucknell University, John received his medical and scientific education at Drexel University, and residency and fellowship training at Duke. He has authored over scientific publications. Maude is a deal maker and company builder with over 17 years of business development corporate strategy, and cross functional business experience in public and private biotechnology, pharmaceutical and academic organizations.
